RNAC
Cartesian Therapeutics, Inc.NASDAQHealthcare$6.26-2.03%ClosedMarket Cap: $165.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.28
P/S
59.14
EV/EBITDA
-0.86
DCF Value
$3.76
FCF Yield
-48.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-357.5%
Operating Margin
-3099.9%
Net Margin
-4658.6%
ROE
279.6%
ROA
-44.0%
ROIC
-28.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $947.0K | 100.0% | $-21.9M | $-92.6M | $-3.46 | — |
| FY 2025 | $2.8M | 100.0% | $-86.7M | $-130.3M | $-5.02 | — |
| Q3 2025 | $452.0K | -2731.2% | $-21.1M | $-35.9M | $-1.38 | — |
| Q2 2025 | $298.0K | 100.0% | $-21.8M | $15.9M | $0.60 | — |
| Q1 2025 | $1.1M | 100.0% | $-21.9M | $-17.7M | $-0.68 | — |
| Q4 2024 | $-759.0K | 100.0% | $-26.7M | $-10.3M | $-0.07 | — |
| FY 2024 | $38.9M | 100.0% | $-43.9M | $-77.4M | $-3.29 | — |
| Q3 2024 | $387.0K | 100.0% | $-17.6M | $-24.2M | $-1.13 | — |
| Q2 2024 | $33.4M | 100.0% | $13.8M | $13.8M | $0.54 | — |
| Q1 2024 | $5.8M | 100.0% | $-13.3M | $-56.8M | $-10.50 | — |
| Q4 2023 | $8.3M | 100.0% | $-36.3M | $-177.7M | $-41.56 | — |
| FY 2023 | $26.0M | 100.0% | $-86.4M | $-219.7M | $-49.76 | — |